Shareholder Tools

Investor Relations

Investor Relations

NASDAQ: ECYT
$1.31 - 0.01
Aug 16, 2017 at 4:00 PM ET
Intraday data provided by eSignal

Corporate Profile

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.

In addition, the Company continues to pursue applications of the SMDC platform and is working to bring assets toward clinical development in several areas, including EC2629, its dual-targeted DNA crosslinker drug that can attack both tumor associated macrophages (“TAMs”) and cancer cells, and its chimeric antigen receptor T-cell (“CAR T-Cell”) SMDC adaptor platform.

Press ReleasesView All

Endocyte Announces Presentations at the 254th American Chemical Society National Meeting & Exposition
WEST LAFAYETTE, Ind., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates...

Read More

Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update
- Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 - - Nearing Completion of Enrollment of Expansion Phase o...

Read More